Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
GSK-3 Inhibitor
GSK-3 Inhibitor 3 is a selective inhibitor targeting glycogen synthase kinase 3 (GSK-3) with notable brain penetration. It exhibits low nanomolar potency, with IC50 values of 0.35 nM for GSK-3α and 0.25 nM for GSK-3β. This compound effectively reduces tau protein phosphorylation at the S396 site in a triple-transgenic mouse model of Alzheimer's disease, demonstrating an IC50 of 10 nM. GSK-3 Inhibitor 3 is valuable for research into neurological diseases and related signaling pathways. -
GSK3 Inhibitor
CHIR 98024 is a potent glycogen synthase kinase 3 (GSK3) inhibitor with an EC50 of 0.2566 μM. This compound modulates various signaling pathways, contributing to cellular processes such as proliferation, differentiation, and metabolism. CHIR 98024 is utilized in research exploring its therapeutic potential in neurodegenerative diseases, cancer, and other disorders associated with GSK3 dysregulation. -
GSK3β Inhibitor
GSK-3β Inhibitor XI is a selective inhibitor of glycogen synthase kinase 3 beta (GSK-3β) with a potent Ki value of 25 nM. This compound enhances glycogen synthase (GS) activity, making it valuable for investigations into metabolic disorders such as type 2 diabetes and neurodegenerative diseases, including Alzheimer’s disease. Its specificity and potency render it a useful tool for elucidating the role of GSK-3β in various biological processes and therapeutic contexts. -
GSK3 Inhibitor
SAR502250 is a potent and selective ATP-competitive inhibitor of glycogen synthase kinase 3 (GSK3) with an IC50 of 12 nM for human GSK-3β. This compound is orally active and exhibits the ability to penetrate the blood-brain barrier. SAR502250 demonstrates antidepressant-like activity and is applicable for research into Alzheimer's disease and related neurological conditions. -
GSK3/CDK9 Inhibitor
ABC1183 is a selective dual inhibitor targeting GSK3 and CDK9, effectively inhibiting GSK3β, GSK3α, and CDK9/cyclin T1 with IC50 values of 657 nM, 327 nM, and 321 nM, respectively. This compound exhibits notable anti-inflammatory and anti-tumor activities, making it a valuable tool for cancer research and inflammation-related studies. Its ability to modulate critical signaling pathways positions ABC1183 as a promising candidate for further investigation in therapeutic applications. -
GSK-3 Inhibitor
GSK3-IN-1 is a selective inhibitor of glycogen synthase kinase 3 (GSK-3) with an IC50 value of 12 μM. This compound is involved in various signaling pathways and plays a critical role in glucose metabolism and insulin signaling. GSK3-IN-1 is particularly relevant for research applications focused on diabetes and other metabolic disorders. -
GSK3β Inhibitor
GSK3β Inhibitor II is a selective inhibitor targeting glycogen synthase kinase 3 beta (GSK3β). This compound exhibits significant activity in modulating GSK3β activity, making it a valuable tool for studying signaling pathways implicated in neurodegenerative diseases such as Alzheimer’s disease. Its use facilitates research aimed at elucidating the roles of GSK3β in cellular processes and potential therapeutic strategies for AD. -
GSK-3/CDK5/CDK2 Inhibitor
GSK-3/CDK5/CDK2-IN-1 is a potent inhibitor targeting GSK-3, CDK5, and CDK2. This imidazole derivative has demonstrated effectiveness in modulating pathways relevant to tumorigenesis and neurodegenerative disorders. Its ability to inhibit these kinases makes it a valuable tool for investigating mechanisms underlying cancer proliferation and neurodegeneration. -
GSK-3β Inhibitor
(E/Z)-GSK-3β inhibitor 1 is a racemic mixture comprising both (E)- and (Z)-isomers targeting glycogen synthase kinase 3β (GSK-3β). This compound exhibits significant antidiabetic activity, with an IC50 value of 4.9 nM, making it a valuable tool for studying pathways related to glucose metabolism and insulin signaling. Its inhibition of GSK-3β provides insights into potential therapeutic strategies for diabetes and related metabolic disorders. -
GSK-3 Inhibitor
L803-mts is a selective, substrate-competitive inhibitor of glycogen synthase kinase 3 (GSK-3) with an IC50 of 40 μM. This compound has been shown to significantly reduce amyloid-beta (Aβ) deposits and improve cognitive deficits in the 5XFAD mouse model of Alzheimer's disease. Additionally, L803-mts exhibits antidepressant-like effects, as demonstrated in the forced swimming test, making it a valuable tool for studying neurodegenerative and mood disorders. -
GSK-3β Inhibitor
GSK-3β inhibitor 8 is a selective inhibitor of glycogen synthase kinase 3 beta (GSK-3β) with an IC50 value of 64 nM. This thiophenacil derivative targets the Wnt signaling pathway, leading to its negative regulation and promoting β-cell proliferation. GSK-3β inhibitor 8 is valuable for research involving cell signaling, diabetes, and regenerative medicine applications. -
GSK-3β Inhibitor
COB-187 is a selective and potent ATP-competitive inhibitor of Glycogen Synthase Kinase 3 beta (GSK-3β). This compound operates through a reversible mechanism dependent on Cysteine (Cys)-199, effectively inhibiting GSK-3β activity. COB-187 is shown to reduce cytokine production induced by lipopolysaccharides (LPS) and decreases CXCL10 production triggered by SARS-CoV-2 spike protein, making it relevant for research in inflammation and viral response studies. -
GSK-3 Inhibitor
GSK-3 Inhibitor XIII is a potent ATP-competitive inhibitor of glycogen synthase kinase 3 (GSK-3), exhibiting a Ki value of 24 nM. It effectively modulates GSK-3 activity, making it a valuable tool for studying various biological processes, including cell growth, differentiation, and metabolism. This inhibitor is particularly relevant for research in cancer, neurodegenerative diseases, and diabetes, as it plays a critical role in signaling pathways associated with these conditions. -
GSK-3β Inhibitor
TCS2002 is a potent and selective inhibitor of GSK-3β, demonstrating an IC50 of 35 nM. This compound exhibits favorable pharmacokinetic properties, including efficient blood-brain barrier penetration. TCS2002 is valuable for research related to Alzheimer’s disease and the investigation of associated neurodegenerative mechanisms. -
GSK-3 Inhibitor
BIP-135 is a selective ATP-competitive inhibitor of glycogen synthase kinase 3 (GSK-3) with IC50 values of 16 nM for GSK-3α and 21 nM for GSK-3β. This compound demonstrates neuroprotective effects, making it a valuable tool in research focused on neurodegenerative diseases and related pathways. Its specificity and potency position BIP-135 as a significant reagent for studying GSK-3-related biological processes. -
GSK-3/CDK2/CDK5 Inhibitor
GSK-3 Inhibitor 4 is a potent inhibitor of Glycogen Synthase Kinase 3 (GSK-3), Cyclin-Dependent Kinase 2 (CDK2), and Cyclin-Dependent Kinase 5 (CDK5), demonstrating IC50 values of 0.56 nM for GSK-3β, 0.45 nM for GSK-3α, 0.47 μM for CDK2, and 0.68 μM for CDK5. This compound effectively attenuates the phosphorylation of Tau protein, making it a valuable tool for investigating mechanisms underlying Alzheimer's disease. Its oral bioavailability and ability to penetrate the blood-brain barrier further enhance its utility in neuropharmacological research. -
GSK-3β Inhibitor
GSK-3β inhibitor 10 is a potent inhibitor of glycogen synthase kinase 3 beta (GSK-3β) with an IC50 value of 80.5 nM. This compound is valuable for studies investigating the role of GSK-3β in various neurodegenerative disorders, particularly Alzheimer’s disease. Its inhibitory action on GSK-3β may contribute to understanding the molecular mechanisms underlying these conditions and aid in the development of targeted therapeutic strategies. -
GSK3 Inhibitor
(R)-BRD3731 is a selective glycogen synthase kinase 3 (GSK3) inhibitor. It demonstrates inhibitory activity with IC50 values of 1.05 μM for GSK3β and 6.7 μM for GSK3α. This compound is utilized in research focused on understanding GSK3's role in various cellular processes and diseases, including diabetes, neurodegenerative disorders, and cancer. As a valuable tool for studying GSK3 modulation, (R)-BRD3731 facilitates the exploration of therapeutic strategies that target this kinase. -
GSK-3β Inhibitor
GSK-3β Inhibitor 11 is a specific inhibitor of glycogen synthase kinase-3β (GSK-3β) with an IC50 value of 10.02 μM. This compound plays a significant role in modulating signaling pathways involved in neurodegenerative diseases, making it a valuable tool for research in this area. Its ability to selectively inhibit GSK-3β enables investigations into its potential therapeutic effects on associated pathological mechanisms. -
GSK3 Inhibitor
GSK3-IN-9 is a selective inhibitor of glycogen synthase kinase 3 (GSK3). This compound exhibits notable biological activity in neurodevelopmental and psychiatric disorders, including Fragile X syndrome and attention deficit hyperactivity disorder (ADHD). Additionally, GSK3-IN-9 shows potential applicability in research related to childhood seizures, intellectual disabilities, diabetes, acute myeloid leukemia (AML), autism, and other psychiatric disorders. -
GSK3 Inhibitor
GSK3-IN-2 is a potent inhibitor of glycogen synthase kinase 3 (GSK3), a key regulator of various cellular processes, including metabolism, cell differentiation, and apoptosis. This compound selectively inhibits GSK3 activity, leading to increased levels of β-catenin and modulation of Wnt signaling pathways. GSK3-IN-2 is valuable for research in cancer biology, neurodegenerative diseases, and regenerative medicine, where GSK3's role in cellular signaling and function is of significant interest. -
GSK3 inhibitor
GS87 is a selective GSK3 inhibitor, demonstrating IC50 values of 415 nM for GSK3α and 521 nM for GSK3β. It effectively activates GSK3-dependent signaling pathways, including MAPK signaling, leading to differentiation of acute myeloid leukemia (AML) cell lines. GS87 exhibits superior modulation of key GSK3 target proteins associated with cell proliferation and differentiation compared to alternative GSK3 inhibitors. This compound holds promise as a differentiation agent for research involving non-promyelocytic AML. -
GSK-3b Inhibitor
GSK3β-IN-1 is a potent inhibitor of glycogen synthase kinase-3β (GSK-3β), with an IC50 value of 65 nM. This compound plays a crucial role in the modulation of key signaling pathways involved in neuronal function and is particularly relevant in the context of Alzheimer's disease research. Its application extends to investigating GSK-3β's involvement in various cellular processes and potential therapeutic strategies for neurodegenerative disorders. -
TbGSK3 Inhibitor
Antitrypanosomal agent 14 is a selective inhibitor of TbGSK3, demonstrating an IC50 of 12 μM and an EC50 of 0.47 μM against Trypanosoma brucei. This compound is primarily utilized in research focused on Human African trypanosomiasis, aiding in the exploration of therapeutic strategies against this parasitic infection. Its targeted mechanism suggests potential for further studies in drug development and disease management. -
CK1γ/GSK3β Inhibitor
AKI-062a is a non-selective inhibitor targeting CK1γ and GSK3β, key regulators in the WNT signaling pathway. It exhibits an ability to modulate various kinase activities, binding to 17 kinases at 1 μM concentration, with a relative activity of less than 10% compared to controls. This compound is valuable for research applications related to cell signaling, cancer biology, and developmental processes where WNT signaling is involved. -
CDK/GSK-3 Inhibitor
CDK5-IN-4 is a potent multikinase type-II inhibitor primarily targeting cyclin-dependent kinase 5 (CDK5), with an IC50 of 9.8 μM. Additionally, it exhibits inhibitory activity against GSK-3α and GSK-3β with IC50 values of 0.98 μM and 4.00 μM, as well as CDK9 and CDK2, with IC50 values of 1.76 μM and 6.24 μM, respectively. This compound is particularly relevant for research on glioblastoma and may aid in understanding its molecular mechanisms. -
AChE/BACE1/GSK3β Inhibitor
AChE/BACE1/GSK3β-IN-1 is a potent triple inhibitor targeting acetylcholinesterase (AChE), beta-secretase 1 (BACE1), and glycogen synthase kinase 3 beta (GSK3β). It demonstrates effective inhibitory activity with IC50 values of 1.0 μM for AChE, 20 μM for BACE1, and 15 μM for GSK3β. With favorable blood-brain barrier penetrability and bioavailability, AChE/BACE1/GSK3β-IN-1 is a valuable tool for research into Alzheimer's disease mechanisms and therapeutics. -
AChE/GSK-3β Inhibitor
ZLWH-23 is a selective inhibitor of acetylcholinesterase (AChE) with an IC50 of 0.27 μM and also inhibits glycogen synthase kinase-3 beta (GSK-3β) with an IC50 of 6.78 μM. It exhibits greater selectivity for AChE compared to butyrylcholinesterase (BChE) and shows preferential inhibition of GSK-3β over a range of multi-kinases. This compound is relevant for research focused on Alzheimer's disease pathophysiology. -
GSK-3β Inhibitor
GSK-3β Inhibitor 12 is a selective inhibitor of glycogen synthase kinase-3 beta (GSK-3β), demonstrating a significant reduction in enzymatic activity by 49.11% at 25 μM and 37.11% at 50 μM concentrations. This compound is valuable for research into neurodegenerative diseases, providing insights into GSK-3β's role in cellular processes and disease mechanisms. Its application may facilitate the development of therapeutic strategies targeting GSK-3β-related pathways. -
GSK-3β inhibitor
3F8 is a potent and selective inhibitor of glycogen synthase kinase-3 beta (GSK-3β). It demonstrates significant biological activity in modulating GSK-3β signaling pathways, making it a valuable tool for research into various GSK-3β associated diseases, including neurodegeneration and cancer. This compound holds potential as a therapeutic candidate, offering insights into the regulatory roles of GSK-3β in cellular processes. -
GSK-3 Inhibitor
CHIR-21208 is a highly selective inhibitor of glycogen synthase kinase-3 (GSK-3), a critical regulator in various cellular processes. This compound demonstrates significant potential in the study of neurodegenerative diseases, including Alzheimer's disease, as well as metabolic disorders such as type 2 diabetes. Researchers can utilize CHIR-21208 to explore GSK-3's role in signaling pathways and its implications in disease mechanisms. -
AChE/GSK-3β Inhibitor
PJ17 is a potent dual inhibitor of acetylcholinesterase (AChE) and glycogen synthase kinase 3 beta (GSK-3β), exhibiting IC50 values of 8.84 μM and 4.19 μM, respectively. This compound demonstrates a lack of significant neurotoxicity in primary cerebellar granule neuron cultures, making it a promising candidate for neuropharmacological studies. PJ17 serves as a valuable template for the development of multitarget therapeutics and is relevant in research focused on Alzheimer's disease. -
GSK-3 Inhibitor
GSK3-IN-11 is a selective inhibitor of Glycogen Synthase Kinase-3 (GSK-3), exhibiting an IC50 of 5010 nM. This compound plays a critical role in regulating various cellular processes, including glycogen metabolism, cell cycle progression, and apoptosis. GSK3-IN-11 is utilized in research to study GSK-3-related signaling pathways and its implications in diseases such as diabetes, cancer, and neurodegenerative disorders. -
GSK3 Inhibitor
GSK3-IN-4 is a potent glycogen synthase kinase 3 (GSK3) inhibitor, specifically designed to modulate GSK3 activity. This compound has demonstrated significant biological activity relevant to the study of psychiatric disorders, making it a valuable tool for exploring the molecular mechanisms underlying these conditions. GSK3-IN-4's inhibition of GSK3 opens avenues for therapeutic research and the development of novel treatments targeting neurological diseases. -
GSK3β Inhibitor
GSK3β-IN-3 is an ATP-competitive inhibitor of glycogen synthase kinase 3 beta (GSK3β), exhibiting an IC50 of 0.90 μM. It effectively lowers the phosphorylation levels of tau protein in the BR5706 strain and reduces the accumulation of amyloid-beta (Aβ) aggregates in the CL2006 strain. This compound is essential for research applications focused on Alzheimer's disease (AD), aiding in the understanding of neurodegenerative mechanisms and potential therapeutic strategies. -
GSK3 Inhibitor
CHIR-98023 is a selective and reversible inhibitor of glycogen synthase kinase 3 (GSK3), demonstrating IC50 values of 10 nM for GSK3α and 6.7 nM for GSK3β. This compound enhances insulin signaling and glucose metabolism, making it valuable for research in diabetes and metabolic disorders. Its specificity for GSK3 further supports its potential in elucidating the pathways associated with cell signaling and energy homeostasis. -
GSK-3β/α Inhibitor
MJ34 is a potent inhibitor of glycogen synthase kinase-3 beta (GSK-3β) and alpha (GSK-3α), exhibiting IC50 values of 15.4 nM and 31.5 nM, respectively. This compound is critical for studies investigating the role of GSK-3 in cancer biology, including cellular signaling pathways and disease progression. MJ34’s ability to selectively inhibit these kinases makes it a valuable tool for exploring therapeutic strategies in cancer research. -
GSK3β Inhibitor
GSK3β-IN-4 is a potent and selective ATP-competitive inhibitor of GSK3β, exhibiting an IC50 of 0.37 nM. This compound also shows activity against GSK3α with an IC50 of 2.75 nM and a selectivity index of 7.4. GSK3β-IN-4 effectively reduces tau phosphorylation at Ser396 and has demonstrated improvements in cognitive deficits in Alzheimer's disease models. It is suitable for research focused on Alzheimer's disease pathophysiology and potential therapeutic interventions. -
GSK-3α Inhibitor
(Rac)-BRD0705 is a racemic mixture that functions as a selective inhibitor of GSK-3α, exhibiting an IC50 of 66 nM and a Kd of 4.8 μM. This compound demonstrates a notable selectivity for GSK-3α, being eight times more potent than for GSK-3β, which has an IC50 of 515 nM. (Rac)-BRD0705 is relevant for research applications involving acute myeloid leukemia (AML) and other conditions where GSK-3 inhibition may play a critical role in disease mechanisms. -
GSK-3β Inhibitor
TC-G 24 is a selective glycogen synthase kinase-3β (GSK-3β) inhibitor, exhibiting an IC50 of 17.1 nM. This compound is capable of crossing the blood-brain barrier, making it valuable for research on various neurological and metabolic disorders, including type 2 diabetes mellitus, stroke, and Alzheimer's disease. TC-G 24 offers a useful tool for investigating the therapeutic potential of GSK-3β modulation in relevant disease models. -
GSK-3β Inhibitor
GSK-3β inhibitor 17 is a potent inhibitor of glycogen synthase kinase 3 beta (GSK-3β). This compound demonstrates a capacity to reduce cisplatin-induced phosphorylation of p65 and the expression of KIM-1 protein and mRNA. Additionally, GSK-3β inhibitor 17 effectively lowers the mRNA levels of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, and MCP-1. It exhibits anti-inflammatory properties and holds promise for research into acute kidney injury. -
hAChE/hBuChE Inhibitor
hAChE-IN-5 is a potent inhibitor of human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBuChE), exhibiting IC50 values of 0.17 μM for both enzymes. In addition, hAChE-IN-5 demonstrates significant GSK3β inhibition with an IC50 of 0.21 μM. This compound is utilized in research focused on tau protein aggregation and Aβ1-42 self-aggregation, effectively preventing Aβ-dependent neurotoxicity. Furthermore, hAChE-IN-5 can cross the blood-brain barrier, showcasing its potential as a multi-targeted agent in the study of Alzheimer's disease. -
GSK-3β inhibitor
GSK-3β inhibitor 20 is a potent inhibitor of glycogen synthase kinase 3 beta (GSK-3β) with an IC50 value of 74.4 nM. This compound is primarily utilized in research applications aimed at understanding the role of GSK-3β in various signaling pathways, including those involved in metabolism, neurodegenerative diseases, and cancer. Its effective inhibition can provide insights into GSK-3β functions and facilitate the development of therapeutic strategies targeting this kinase. -
GSK-3β Inhibitor
18BIOder is a selective inhibitor of Glycogen Synthase Kinase 3 beta (GSK-3β) with notable neuroprotective properties. This compound has demonstrated efficacy in inhibiting HIV-1, contributing to its potential therapeutic applications in neurodegenerative diseases and HIV research. 18BIOder serves as a valuable tool for understanding the mechanistic pathways involved in GSK-3β modulation and its effects on cell signaling. -
GSK-3 Inhibitor
GSK-3 Inhibitor 6 is a potent inhibitor of glycogen synthase kinase 3 (GSK-3), displaying IC50 values of 29 nM for GSK-3α and 24 nM for GSK-3β. This compound demonstrates effective central nervous system penetration, making it suitable for neurological research. It is beneficial for studying GSK-3-related pathways in various biological contexts, including cell signaling and neurodegenerative disease models. -
GSK-3β Inhibitor
JGK-263 is an orally active inhibitor of Glycogen synthase kinase-3β (GSK-3β). It demonstrates neuroprotective properties and has the potential to enhance motor function. This compound is suitable for research applications related to neurological disorders, including amyotrophic lateral sclerosis (ALS). -
GSK-3 Inhibitor
PIMPC is a novel inhibitor of glycogen synthase kinase 3 (GSK-3), a key regulator in various cellular processes. This compound exhibits antioxidant and metal-chelating properties, contributing to its potential applications in neuroprotection. Research indicates that PIMPC may offer therapeutic benefits in conditions such as Alzheimer's disease, making it a valuable tool for studies focused on neurodegenerative disorders and GSK-3 modulation. -
CDK/GSK3 Inhibitor
Aloisine RP106 is a potent inhibitor of cyclin-dependent kinases (CDKs) Cdk1/cyclin B and Cdk5/p25, as well as glycogen synthase kinase 3 (GSK3), with IC50 values of 0.70 µM, 1.5 µM, and 0.92 µM, respectively. This compound is valuable for research applications targeting cell cycle regulation and neurodegenerative diseases, where CDK and GSK3 activity contribute to pathological processes. Researchers can utilize Aloisine RP106 to investigate the role of these kinases in various biological contexts including cancer and neurobiology. -
PfGSK3/PfPK6 Inhibitor
PfGSK3/PfPK6-IN-2 is a potent dual inhibitor of PfGSK3 and PfPK6, with IC50 values of 172 nM and 11 nM, respectively. This compound exhibits significant efficacy in the modulation of key signaling pathways in Plasmodium falciparum, making it a valuable tool for malaria research. Its ability to inhibit these targets can aid in the investigation of therapeutic strategies against malaria. -
GSK-3β Inhibitor
GSK-3β Inhibitor 14 is a benzothiazepinone derivative that acts as a weak inhibitor of glycogen synthase kinase 3 beta (GSK-3β), with an IC50 greater than 100 μM. This compound is utilized in research focusing on GSK-3β-related pathways, potentially contributing to studies in various diseases, including neurodegenerative disorders and metabolic conditions. Its role in modulating GSK-3β activity makes it a valuable tool for elucidating the physiological and pathological functions associated with this important kinase.
